Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert M Sharkey

Showing results (11-20 of 111) with videos related to

Pageof 12
Sort By:
Expert Opinion on Biological Therapy|April 18, 2020
Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapyDavid M Goldenberg, Robert M Sharkey
Expert Review of Clinical Immunology|May 19, 2010
Radioimmunotherapy of non-Hodgkin's lymphoma: a critical appraisalRobert M Sharkey, Jack Burton, David M Goldenberg
Cancer|February 4, 2010
Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclidesRobert M Sharkey, Habibe Karacay, David M Goldenberg
Oncotarget|July 11, 2018
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer targetDavid M Goldenberg, Rhona Stein, Robert M Sharkey
Blood|February 3, 2009
A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapyRobert M Sharkey, Oliver W Press, David M Goldenberg
Cancer Research|November 25, 2003
Meeting report on the Ninth Conference on Cancer Therapy with Antibodies and ImmunoconjugatesRobert M Sharkey, Edward A Sausville, David M Goldenberg
Cancer Biotherapy & Radiopharmaceuticals|September 21, 2010
Renal dosimetry in peptide radionuclide receptor therapyJeffry A Siegel, Michael G Stabin, Robert M Sharkey
EJNMMI Research|May 9, 2013
Radiofluorination using aluminum-fluoride (Al18F)William J McBride, Robert M Sharkey, David M Goldenberg
Expert Opinion on Biological Therapy|April 6, 2016
Prospects and progress of antibody-drug conjugates in solid tumor therapiesSerengulam V Govindan, Robert M Sharkey, David M Goldenberg
Molecular Cancer Therapeutics|April 7, 2011
Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft modelsRobert M Sharkey, Habibe Karacay, Serengulam V Govindan, et al.
Pageof 12

Showing results (11-20 of 111) with videos related to

Sort By:
Pageof 12
Expert Opinion on Biological Therapy|April 18, 2020
Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapyDavid M Goldenberg, Robert M Sharkey
Expert Review of Clinical Immunology|May 19, 2010
Radioimmunotherapy of non-Hodgkin's lymphoma: a critical appraisalRobert M Sharkey, Jack Burton, David M Goldenberg
Cancer|February 4, 2010
Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclidesRobert M Sharkey, Habibe Karacay, David M Goldenberg
Oncotarget|July 11, 2018
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer targetDavid M Goldenberg, Rhona Stein, Robert M Sharkey
Blood|February 3, 2009
A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapyRobert M Sharkey, Oliver W Press, David M Goldenberg
Cancer Research|November 25, 2003
Meeting report on the Ninth Conference on Cancer Therapy with Antibodies and ImmunoconjugatesRobert M Sharkey, Edward A Sausville, David M Goldenberg
Cancer Biotherapy & Radiopharmaceuticals|September 21, 2010
Renal dosimetry in peptide radionuclide receptor therapyJeffry A Siegel, Michael G Stabin, Robert M Sharkey
EJNMMI Research|May 9, 2013
Radiofluorination using aluminum-fluoride (Al18F)William J McBride, Robert M Sharkey, David M Goldenberg
Expert Opinion on Biological Therapy|April 6, 2016
Prospects and progress of antibody-drug conjugates in solid tumor therapiesSerengulam V Govindan, Robert M Sharkey, David M Goldenberg
Molecular Cancer Therapeutics|April 7, 2011
Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft modelsRobert M Sharkey, Habibe Karacay, Serengulam V Govindan, et al.
Pageof 12